INDIANAPOLIS, Nov. 23, 2010 (GLOBE NEWSWIRE) -- Positron Corporation (OTCBB:POSC), a molecular imaging solutions company focused on Nuclear Cardiology, will attend the 96th Scientific Assembly and Annual Meeting (RSNA) in Chicago, Illinois, being held November 28th to December 3rd , 2010.
RSNA is an association of more than 44,000 radiologists, radiation oncologists, medical physicists and related scientists committed to excellence in patient care through education and research. This year's conference will feature over 2,400 scientific presentations and posters covering the newest trends in radiological research, and more than 1,900 education and informatics exhibits. Attendees will have the opportunity to interview experts in all radiologic subspecialties and related fields.
Joseph Oliverio, chief technology officer of Positron states, "The RSNA Annual Meeting is the biggest and most prestigious forum hosting the latest most cutting-edge information in radiology and medical imaging of any meeting, anywhere in the world. It's an ideal fit for Positron to exhibit its unique and relevant position in the nuclear medicine community."
The Company is anticipating a high level of interest in its Attrius® cardiac specific PET scanner and, more specific to this radiology-based conference, its Nuclear Pharm-Assist®, an FDG automated compounding, handling and shielding device and Tech-Assist™, an FDG dose administration and shielding system.
The mission of the RSNA meeting is to promote and develop the highest standards of radiology and related sciences through education and research to advance the quality of healthcare provided. For further information please visit the RSNA website at www.rsna.org.
About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attrius®, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assist™, a radiopharmaceutical injection shield. More information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.